Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | METAP2 | P50579 | 14/20 | 0.42 |
| ▸ | METAP1 | P53582 | 4/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12402193 | 0.91 | EPHX1 (0.39) | EPHX1METAP2METAP1 | |
| SCHEMBL5848754 | 0.77 | METAP2 (0.50) | EPHX1METAP2METAP1DPP4 | |
| SCHEMBL5850001 | 0.76 | METAP2 (0.53) | EPHX1METAP2METAP1DPP4 | |
| SCHEMBL5849705 | 0.76 | METAP2 (0.53) | EPHX1METAP2METAP1DPP4 | |
| SCHEMBL8247186 | 0.75 | METAP2 (0.46) | EPHX1METAP2METAP1DPP4 | |
| SCHEMBL1593125 | 0.75 | METAP2 (0.52) | EPHX1METAP2METAP1 | |
| SCHEMBL8089041 | 0.73 | — | — | |
| SCHEMBL5485166 | 0.73 | — | — | |
| SCHEMBL14895039 | 0.70 | EPHX1 (0.54) | EPHX1DPP4 | |
| SCHEMBL21854171 | 0.69 | METAP2 (0.40) | METAP2METAP1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103508918-B | With the Alpha-hydroxy beta-amino ester compound and preparation method thereof of cyclobutyl | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-09-09 | — | — | CN | disclosed |
| CN-103508918-A | Cyclobutyl-containing alpha-hydroxy-beta-amino ester compound and preparation method thereof | SHANGHAI INST PHARM INDUSTRY | 2014-01-15 | — | — | CN | disclosed |
| US-7759499-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | EPHX1 1063/4885METAP2 109/4885METAP1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.